Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Enthusiasm With EGFR Exon 20+ in NSCLC

June 28th 2021

Joshua K. Sabari, MD; Jamie Chaft, MD; and Vamsidhar Velcheti, MD, highlight the intriguing data in the realm of EGFR exon 21 insertion mutations in non–small cell lung cancer presented during the 2021 ASCO Annual Meeting.

Kicking Off With KRAS in NSCLC

June 28th 2021

OncLive’s third episode of Thoracic Night Live, a program devoted to spotlighting the biggest topics in lung cancer and pivotal studies discussed at medical meetings throughout the year, focuses on findings presented at the 2021 ASCO Annual Meeting.

Lopes Shines a Light on the Explosion of Targeted Therapies in Lung Cancer Treatment Arsenal

June 26th 2021

Gilberto Lopes, MD, discusses the latest developments made in the treatment of patients with non–small cell lung cancer whose tumors harbor genetic alterations and the clinical implications of recent regulatory approvals.

FDA Grants Breakthrough Therapy Designation to Adagrasib for KRAS G12C–Mutated NSCLC

June 25th 2021

The FDA has granted a breakthrough therapy designation to adagrasib for use as a potential therapeutic option for patients with KRAS G12C–mutated non–small cell lung cancer following previous systemic therapy.

Olaparib Approved in China for BRCA+ Metastatic Castration-Resistant Prostate Cancer

June 24th 2021

The Chinese National Medical Products Administration has granted conditional approval to olaparib for use as a monotherapy in the treatment in adult patients with germline or somatic BRCA-mutated, metastatic castration-resistant prostate cancer who have progressed after previous treatment that included a new hormonal agent like abiraterone acetate or enzalutamide.

Dr. Schram on the Results of the Phase 1/2 eNRGy Trial in NRG1+ Solid Tumors

June 24th 2021

Alison Schram, MD, discusses the results of the phase 1/2 eNRGy trial, which were presented during the 2021 ASCO Annual Meeting, in NRG1 fusion–positive solid tumors.

Frontline Domvanalimab-Based Combos Elicit Encouraging ORRs in PD-L1–High NSCLC

June 24th 2021

The anti-TIGIT agent domvanalimab in combination with zimberelimab with or without etrumadenant demonstrated promising objective response rates when given as a first-line treatment in patients with metastatic non–small cell lung cancer who have a PD-L1 expression of 50% or higher.

Treatment of Unresectable EGFR-Mutated NSCLC

June 24th 2021

Key opinion leaders in lung cancer have a lively discussion on the challenges associated with making treatment decisions for patients with unresected stage III EGFR-mutated NSCLC.

Treatment Approaches After Adjuvant Osimertinib

June 24th 2021

A panel of thought leaders in the management of NSCLC review best practices for monitoring patients and making treatment decisions after adjuvant osimertinib.

Dr. Malhotra on the Safety Profile of Plinabulin/Nivolumab/Ipilimumab in Relapsed SCLC

June 23rd 2021

Jyoti Malhotra, MD, MPH, discusses the safety profile of plinabulin in combination with nivolumab and ipilimumab in relapsed/refractory small cell lung cancer.

Savolitinib Approved in China for METex14+ NSCLC

June 23rd 2021

Savolitinib has been granted a conditional approval in China for use in patients with non–small cell lung cancer with MET exon 14 skipping alterations who experienced disease progression after previous systemic therapy or are unable to receive chemotherapy.

MET Inhibitors Find Their Niche in NSCLC

June 23rd 2021

Three-quarters of all cases of lung adenocarcinoma, the most common type of non–small cell lung cancer, are defined by oncogenic driver events involving receptor tyrosine kinase–orchestrated cellular signaling pathways.

Dr. Spira on the Updated Results of the CHRYSALIS Trial in EGFR-Mutant NSCLC

June 22nd 2021

Alexander Spira, MD, PhD, FACP, discusses the updated results of the phase 1 CHRYSALIS trial in EGFR-mutant non–small cell lung cancer.

Dr. Liu on the Rationale for the ARROW Trial in RET Fusion+ NSCLC

June 22nd 2021

Stephen Liu, MD, discusses the rationale for the ongoing phase 1/2 ARROW trial in RET fusion–positive non–small cell lung cancer.

Dr. Pennell on Understanding the Cost-Effectiveness of Osimertinib in NSCLC

June 22nd 2021

Nathan A. Pennell, MD, PhD, discusses the importance of understanding the cost-effectiveness of osimertinib in non–small cell lung cancer.

Experts Break Down Exciting Breakthroughs in NSCLC

June 22nd 2021

Experts in lung cancer discuss advances with targeted therapies in non–small cell lung cancer, highlighting the latest and most pivotal data in the thoracic space and how the data apply to clinical practice.

Garassino Highlights What’s In Store for Lung Cancer

June 21st 2021

Patients with lung cancer were identified as an at-risk group for developing severe complications as a result of SARS-CoV-2 infection, and thoracic oncologists were fast to respond with the establishment of the Thoracic Cancers International COVID-19 Collaboration.

Rapid Readouts: Updated Results and 5-Year Survival Outcomes From the PACIFIC Trial

June 18th 2021

David R. Spigel, MD, presents data from the 2021 American Society of Clinical Oncology annual meeting on the updated results from the phase 3 PACIFIC trial of durvalumab treatment after chemotherapy in patients with unresectable stage III non-small cell lung cancer

Frontline Sintilimab Plus Gemcitabine/Platinum Prolongs PFS in Squamous NSCLC

June 18th 2021

The addition of sintilimab to standard chemotherapy comprised of gemcitabine and platinum significantly improved progression-free survival with acceptable safety in previously untreated patients with advanced or metastatic squamous non–small cell lung cancer.

Clinical Implications of the ADAURA Trial

June 17th 2021

A panel of key opinion leaders in lung cancer considers the clinical implications of the ADAURA trial of adjuvant osimertinib and discuss how results may affect the treatment landscape in early stage NSCLC.